Interleukin-6 as a therapeutic target

Clinical Cancer Research

Volumn 21, Issue 6, 2015, Pages 1248-1257

  Rossi, Jean François ^a,b,c   Lu, Zhao Yang ^d   Jourdan, Michel ^b   Klein, Bernard ^b,c  

^a HÔPITAL SAINT ELOI   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ARGX 109; BORTEZOMIB; C REACTIVE PROTEIN; CARBOPLATIN; CLAZAKIZUMAB; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXORUBICIN; ELSILIMOMAB; FM 101; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY 8; MONOCLONAL ANTIBODY BE 4; OLOKIZUMAB; PEGINTERFERON ALPHA2B; PLACEBO; PREDNISONE; SANT 7; SARILUMAB; SILTUXIMAB; SIRUKUMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 30; IL6 PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; HUMAN; INFECTION; KIDNEY CARCINOMA; MONOTHERAPY; MULTIPLE MYELOMA; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; GIANT LYMPH NODE HYPERPLASIA; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; CELL PROLIFERATION; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INFLAMMATION; INTERLEUKIN-6; MICE; NEOPLASMS; RECEPTORS, INTERLEUKIN-6;

EID: 84927610492     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2291     Document Type: Review

References (79)

1. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324:73-76.
2. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
3. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014;6:1-16.
4. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014;70:11-20.
5. Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 2012;23:85-97.
6. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
7. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991;78:1198-204.
8. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988;332:83-85.
9. Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989;74:11-13.
10. Opp M, Obal F Jr, Cady AB, Johannsen L, Krueger JM. Interleukin-6 is pyrogenic but not somnogenic. Physiol Behav 1989;45:1069-72.
11. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685-91.
12. Blay JY, Favrot M, Rossi JF, Widjenes J. Role of interleukin-6 in paraneo-plastic thrombocytosis. Blood 1993;82:2261-62.
13. Rossi JF, Fegueux N, Lu ZY, Legouffe E, Exbrayat C, Bozonnat MC, et al. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 ofmelphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant 2005;36:771-79.
14. Navarro S, Debili N, Le Couedic JP, Klein B, Breton-Gorius J, Doly J, et al. Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication. Blood 1991;77:461-71.
15. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36.
16. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 1992;22:2819-24.
17. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995;86:3123-31.
18. Lu ZY, Brailly H, Rossi JF, Wijdenes J, Bataille R, Klein B. Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis. Cytokine 1993;5:578-82.
19. Montero-Julian FA, Klein B, Gautherot E, Brailly H. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995;85:917-24.
20. San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014;123:4136-42.
21. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, et al. A phase II, randomized, double-Blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 2015;90:42-9.
22. Rossi JF, Négrier S, James ND, Kocak I, Hawkins R, Davis H, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010;103:1154-62.
23. Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012;48:85-93.
24. van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014;15:66-74.
25. Xu Z, Bouman-Thio E, Comisar C, Frederick B, VanHartingsvelt B, Marini JC, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72:270-81.
26. Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol 2015;27:21-29.
27. Thomas JM, Daugherty PS. Proligands with protease-regulated binding activity identified from cell-displayed prodomain libraries. Protein Sci 2009;18:2053-59.
28. Campo S, Serlupi-Crescenzi O, Arseni B, Rossi S, Saggio I, Salone B, et al. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma. Cytokine 2005;31:368-74.
29. van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998;102:783-90.
30. Puchalski T, Prabhakar U, Qun J, Berns B, Davis HM. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010;16:1652-61.
31. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012;52:199-19.
32. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010;7:CD008331.
33. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-HatemD, Babinet P, et al. Kaposi's sarcoma- associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276-80.
34. Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 2014;123:2924-33.
35. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001;97:1817-22.
36. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A 1989;86:7547-51.
37. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994;330:602-5.
38. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol Mech Dis 2011;6:249-74.
39. Descamps G, Wuillème-Toumi S, Trichet V, Venot C, Debussche L, Hercend T, et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE16421. J Immunol 2006;177:4218-23.
40. Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009;113:4614-26.
41. Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103:3148-57.
42. Mahtouk K, Moreaux J, Hose D, Rème T, Meissner T, Jourdan M. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 2010;10:198.
43. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, et al. Human C-reactive protein binds activating Fcγ receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 2007;12:252-65.
44. Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ 2000;7:1244-52.
45. Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001;98:2853-55.
46. Zhang XG, Gu ZJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, et al. Ciliary neurotropic factor, interleukin 11, leukemia inbitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994;179:1337-42.
47. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 1998;31:351-57.
48. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum Interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993;53:2118-22.
49. Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol 2012;132:703-10.
50. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 2012;120:3783-92.
51. Sakakibara S, Tosato G. Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res 2011;31:791-801.
52. Bartsch R, Woehrer S, Raderer M, Hejna M. Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. Anticancer Res 2006;26:3187-90.
53. Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007;18:1376-81.
54. Tupitsyn N, Kadagidze Z, Gaillard JP, Sholokhova E, Andreeva L, Liautard J, et al. Functional interaction of the gp80 and gp130 IL-6 receptors in human B cell malignancies. Clin Lab Haematol 1998;20:345-52.
55. Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood 1994;84:2472-79.
56. Bataille R, Zhang XG, Wijdenes J, Schved JF, Klein B. Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia. Med Oncol Tumor Pharmacother 1993;10:185-88.
57. Alberti L, Thomachot MC, Bachelot T, Menetrier-CauxC, Puisieux I, Blay JY. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 2004;111:653-61.
58. Angelo LS, Talpaz M, Kurzrock R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res 2002;62:932-40.
59. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 2006;13:1365-70.
60. Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med 2007;5:51.
61. Costes V, Liautard J, Picot MC, Robert M, Lequeux N, Brochier J, et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol 1997;50:835-40.
62. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diammine-dichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995;55:590-96.
63. Tate J, Olencki T, Finke J, Kottke-Marchant K, Rybicki LA, Bukowski RM. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects. Ann Oncol 2001;12:655-59.
64. Azevedo A, Cunha V, Teixeira AL, Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2011;2:384-96.
65. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007;67:764-73.
66. Komatsu S, Hara N, Ishizaki F, Nishiyama T, Takizawa I, Isahaya E, et al. Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy. Prostate 2012;72:1207-13.
67. Weiss TW, Simak R, Kaun C, Rega G, Pflüger H, Maurer G, et al. Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo. Anticancer Res 2011;31:3273-78.
68. Zhang H, Xu Y, Li L, Liu R, Ma B. The interleukin-6-174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int 2012;88:447-53.
69. Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 2011;71:1455-65.
70. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van Veldhuizen PJ Jr, et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010;16:3028-34.
71. Kwon GT, Jung JI, Song HR, Woo EY, Jun JG, Kim JK, et al. Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling. J Nutr Biochem 2012;23:228-38.
72. Kutikov A, Makhov P, Golovine K, Canter DJ, Sirohi M, Street R, et al. Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. Urol 2011;78:968.e7-11.
73. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610-18.
74. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;17:6083-96.
75. Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 2009;15:5426-34.
76. Labbozzetta M, Notarbartolo M, Poma P, Giannitrapani L, Cervello M, Montalto G, et al. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann NY Acad Sci 2006;1089:268-75.
77. Pistoia V, Bianchi G, Borgonovo G, Raffaghello L. Cytokines in neuroblastoma: from pathogenesis to treatment. Immunother 2011;3:895-907.
78. Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997;72:149-54.
79. Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MRF, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 2014;28:1705-15.